within Pharmacolibrary.Drugs.ATC.G;

model G04CA55
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 2.5e-05,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00027833333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G04CA55</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Doxazosin and finasteride is a combination drug used primarily in the treatment of benign prostatic hyperplasia (BPH) in men. Doxazosin is an alpha-1 adrenergic blocker that relaxes smooth muscle in the prostate and bladder neck, while finasteride is a 5-alpha-reductase inhibitor that lowers levels of dihydrotestosterone, resulting in shrinkage of the enlarged prostate. The fixed-dose combination is marketed in some regions but may not be universally approved or widely used.</p><h4>Pharmacokinetics</h4><p>No published population pharmacokinetic models for the fixed-dose combination of doxazosin and finasteride were identified. The following are estimates based on known pharmacokinetics of individual drugs in healthy adult males, assuming standard oral administration.</p><h4>References</h4><ol><li><p>Pupe, CG, et al., &amp; Cabral, LM (2013). Development of a doxazosin and finasteride transdermal system for combination therapy of benign prostatic hyperplasia. <i>Journal of pharmaceutical sciences</i> 102(11) 4057–4064. DOI:<a href=&quot;https://doi.org/10.1002/jps.23715&quot;>10.1002/jps.23715</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23983168/&quot;>https://pubmed.ncbi.nlm.nih.gov/23983168</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G04CA55;
